Loading...
•
Dec 31, 2019
Supernus Q4 2019 Earnings Report
Reported financial results for Q4 2019.
Key Takeaways
Supernus Pharmaceuticals reported Q4 2019 financial results, with net product sales at $97.9 million and operating earnings at $40.8 million.
Q4 2019 product prescriptions for Trokendi XR and Oxtellar XR totaled 212,780, a 1.4% increase over Q4 2018.
Net product sales for Q4 2019 were $97.9 million, compared to $113.5 million in Q4 2018.
Operating earnings in Q4 2019 were $40.8 million, compared to $39.9 million in Q4 2018.
Net earnings (GAAP) in Q4 2019 were $33.1 million, or $0.62 per diluted share, an increase of 29% on a diluted share basis, as compared to $25.9 million, or $0.48 per diluted share, in the same period last year.
Forward Guidance
The company provided full year 2020 net product sales and operating earnings estimates.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...